Breathe's Non-Invasive Open Ventilation System Approved for Department of Veterans Affairs Federal Supply Schedule
IRVINE, Calif.,/PRNewswire/ -- Breathe Technologies, Inc. received official approval from the Department of Veterans Affairs for its Non-Invasive Open Ventilation (NIOV™) System to be added to the Federal Supply Schedule (FSS). The NIOV System has important benefits for patients with later stage chronic obstructive pulmonary disease (COPD), which is fairly common among the veteran population. Breathe has partnered with Jordan Reses Supply Company, a specialty respiratory distributor into the VA, to lead commercialization efforts. "Breathe is excited to partner with Jordan Reses to provide a life changing therapy for veterans with various forms of respiratory insufficiency," says Larry Mastrovich, President & CEO.
Jordan Reses, a leading small business contractor with a Federal Supply Schedule dating back to 1992, specializes in respiratory products. "Jordan Reses is impressed with the clinical benefits the NIOV System has been able to demonstrate for patients in the home and hospital settings. This is a revolutionary technology that is enabling patients mobility who otherwise would be limited in their activities of daily living," says Steve Baugh, President at Jordan Reses.
The NIOV System is an innovative one-pound ventilation system with a proprietary patient interface. It is designed to facilitate ambulation for adult patients with moderate to severe respiratory insufficiency. It is FDA cleared for adult use in inpatient, outpatient and homecare settings.
About Breathe Technologies, Inc.
Breathe Technologies, Inc., located in Irvine, California, is a developer and manufacturer of innovative medical technologies for treating breathing disorders. The company was founded in 2005 with the goal of transforming the lives of people with respiratory insufficiency by producing innovative therapies that have the potential to dramatically improve quality of life. The Breathe Non-Invasive Open Ventilation (NIOV™) System, featuring the company's proprietary Open-airway platform, is FDA-cleared for use in both the institutional and homecare settings. The company also has a late stage CPAP development program to address the unmet needs in sleep apnea. Breathe has taken an integrated approach focused on an improved user experience that is supported by its innovative design while providing best in class therapy. Investors include Kleiner Perkins Caufield & Byers, Delphi Ventures, Johnson & Johnson Development Corporation, Synergy Partners International, DAG Ventures and Morgan Creek Capital Management. For more information, please visit www.breathetechnologies.com.